RE:RE:RE:RE:Zero enrollment updateHmmmmm...I expect you're aware that Baxter has set up KidneyCo and has a 12 to 18 month time frame to "butterfly" into two public companies. Given reporting time frames they will gear towards end of 2023. They feature the EAA and PMX in their KidneyCo presentation as a feature product and have committed to marketing it Day 1 after FDA approval. Let's assume you're correct and we are still less than 90 patients at the end of 2023. If we are still "Exceeding expectations" I would expect Baxter to make an offer to buy Spectral using KindeyCo public company paper. They aren't going to wait for a 7 year or 8 year you are pushing. End of story - Baxter buyout end of 2023 - big boys always get their way.
Management (Seto/Kellum) only have until end of 2023 to get FDA approval for PMX or they get zero on the huge PSU's. If they continue to fail as you keep on saying their only option is to welcome a Baxter buyout through KidneyCo in 2023 or they will get nothing on their PSU's and/or options.
So long term failure...even with incapable management...is not going beyond the end of 2023 or so. Right now I expect they are working on loading up on cheap options as their last kick at the can. I'll leave it to MM to calculate the potential buyout amount from Baxter through KidneyCo in a less than 90 patient scenario or cross that finish line and get a higher buyout.